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IMPORTANCE Selective serotonin reuptake inhibitor (SSRI) use among pregnant women is
increasing, yet the association between prenatal SSRI exposure and fetal neurodevelopment
is poorly understood. Animal studies show that perinatal SSRI exposure alters limbic circuitry
and produces anxiety and depressive-like behaviors after adolescence, but literature on
prenatal SSRI exposure in humans is limited andmixed.
OBJECTIVE To examine associations between prenatal SSRI exposure and brain development
using structural and diffusionmagnetic resonance imaging (MRI).
DESIGN, SETTING, AND PARTICIPANTS A cohort study conducted at Columbia University
Medical Center and New York State Psychiatric Institute included 98 infants: 16 with in utero
SSRI exposure, 21 with in utero untreatedmaternal depression exposure, and 61 healthy
controls. Data were collected between January 6, 2011, and October 25, 2016.
EXPOSURES Selective serotonin reuptake inhibitors and untreatedmaternal depression.
MAIN OUTCOMES ANDMEASURES Graymatter volume estimates using structural MRI with
voxel-basedmorphometry and white matter structural connectivity (connectome) using
diffusionMRI with probabilistic tractography.
RESULTS The sample included 98mother (31 [32%] white, 26 [27%] Hispanic/Latina, 26
[27%] black/African American, 15 [15%] other) and infant (46 [47%] boys, 52 [53%] girls)
dyads. Mean (SD) age of the infants at the time of the scan was 3.43 (1.50) weeks.
Voxel-basedmorphometry showed significant gray matter volume expansion in the right
amygdala (Cohen d = 0.65; 95% CI, 0.06-1.23) and right insula (Cohen d = 0.86; 95% CI,
0.26-1.14) in SSRI-exposed infants compared with both healthy controls and infants exposed
to untreatedmaternal depression (P < .05; whole-brain correction). In connectome-level
analysis of white matter structural connectivity, the SSRI group showed a significant increase
in connectivity between the right amygdala and the right insula with a large effect size (Cohen
d = 0.99; 95% CI, 0.40-1.57) compared with healthy controls and untreated depression
(P < .05; whole connectome correction).
CONCLUSIONS AND RELEVANCE Our findings suggest that prenatal SSRI exposure has an
association with fetal brain development, particularly in brain regions critical to emotional
processing. The study highlights the need for further research on the potential long-term
behavioral and psychological outcomes of these neurodevelopmental changes.
JAMA Pediatr. doi:10.1001/jamapediatrics.2017.5227
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T he prescription of selective serotonin reuptake inhibi-tor (SSRI) medications for pregnant women has accel-erated over the past 30 years.1 To someextent, this rise
may be attributable to increased awareness of the detrimen-
tal effects ofuntreatedprenatalmaternal depression (PMD)on
womenandchildren,2 alongwithearly studies failing todocu-
ment immediate effects of SSRI exposure in offspring (al-
though later rodent studies document postpubertal
alterations3). However, little is known about the association
between prenatal SSRI exposure and human fetal neurode-
velopment.
Serotonin (5-hydroxytryptamine [5-HT]) plays a vital role
in neurodevelopment. In the fetal brain, 5-HT signaling af-
fectscellproliferation,differentiation,neuronalmigration,net-
work formation, and synaptogenesis.4 The 5-HT transporter
iswidely expressed in the fetal brain in both serotonergic and
nonserotonergic neurons,5 thus providing a developmen-
tally transient target for SSRIs. Atypical serotonergic signal-
ing resulting fromprenatal SSRI exposuremayalter fetal brain
development and subsequent functioning.6
Animal studies support this idea. Perinatal SSRI expo-
sure in rodent studies is associatedwithdelayedmotor devel-
opment, reduced pain sensitivity, disrupted thalamocortical
organization, reduced dorsal raphe neuronal firing, reduced
arborization of 5-HT neurons, and altered limbic and cortical
circuit functioning.7,8 Rodent studies also suggest behavioral
consequences of early-life SSRI exposure, including in-
creases in anxiety and depression-like behaviors in adult-
hood (eg, impaired stress response and grooming, decreased
play),3,9 and suggest that early perturbations in 5-HT signal-
ingmay be associated with neurodevelopment, giving rise to
atypical emotion-related behaviors later in life.
Literature on prenatal SSRI exposure in humans is lim-
ited andmixed. Studies havemost consistently reported that
prenatal SSRI exposure is associated with a shorter gesta-
tional period, lowerbirthweight, lowerApgar scores, andneo-
natal abstinence syndrome.10,11 Initial studies on longer-term
neurodevelopmental consequences have yieldedmixed find-
ings; some studies suggest increased internalizing and exter-
nalizing behaviors during early childhood,11,12 whereas oth-
ers fail to find such associations.13 However, consistent with
animal studies,3 a recent national registry study (including
>15000 prenatally SSRI-exposed offspring) found increased
rates of depression in early adolescence in youth with prena-
tal SSRI exposure.14
Brain imaging provides a window into neurodevelop-
ment, yet human infant and fetal imaging studies of prenatal
SSRI exposure are scarce. A recent electroencephalography
study found reduced interhemispheric connectivity and lower
cross-frequency integration in SSRI-exposed infants, suggest-
inguncouplingof frontal circuitry.15Two infantmagnetic reso-
nance imaging (MRI) studiesdocumentedchanges ingraymat-
ter (GM)andwhitematter (WM) tissueproperties inprenatally
SSRI-exposed infants (eg, altered fractional anisotropy of the
thalamostriatal GM and superior WM fascicule16 and in-
creased mean diffusivity in several major fasciculi17). Al-
though these studies suggest an association between prena-
talSSRIexposureandvariation in fetalbraindevelopment, they
areconfoundedbysamplecharacteristics (eg, inclusionofvery
preterm-born infants) or the lack of an untreated PMD com-
parison group.
Based on prior animal studies, we hypothesized that pre-
natally SSRI-exposed infants would demonstrate altered GM
morphologyandWMconnectivitywithin thecorticolimbic cir-
cuit. To test this, we used deformation-based GMmorphom-
etry anddiffusionprobabilisticWMtractography. Tomore ac-
curatelyassess theassociationbetweenprenatalSSRIexposure
and the infant brain, we considered the following methodo-
logic advances: 2 comparison groups (healthy controls [HCs])
and infants exposed to untreated PMD), optimization of im-




Datawere collectedbetween January6, 2011, andOctober 26,
2016. Participants (pregnant women, aged 18-45 years) were
recruited through obstetricians, midwives, and psychia-
trists. A total of 204 mothers were recruited; 103 infants un-
derwent an MRI scan (eMethods and eTable 1 in the Supple-
ment). Group membership was determined after mothers
completed a prenatal mood and medication assessment (be-
tween 19 and 39weeks’ gestation). Mothers were assigned to
the SSRI group if they self-reported receiving an SSRI at some
point in their pregnancy. Sleeping, nonsedated infants under-
went anMRI sessionwhen theywere approximately 3.43 (SD
1.50) weeks of age. The New York State Psychiatric Institute
Institutional Review Board approved all procedures and par-
ticipants providedwritten informed consent. Participants re-
ceived financial compensation for their participation.
PMD and Psychiatric Symptoms
Groupmembership(PMDvsHC)wasdeterminedduringthepre-
natal assessment based on themother’s depression scores, as-
sessedvia theCenter forEpidemiological StudiesDepression19
scale (scores≥16wereconsidered indicativeof clinically signifi-
cantdepression).Womencompleted theSchedule forAffective
Key Points
Question Is prenatal exposure to selective serotonin reuptake
inhibitors associated with fetal brain development?
Findings In this cohort study including 98 infants, significant gray
matter volume expansion was noted in the amygdala and insula, as
well as an increase in white matter structural connectivity between
these same regions in selective serotonin reuptake
inhibitor–exposed infants, compared with infants exposed to
untreated prenatal maternal depression and healthy controls.
Meaning In line with prior animal studies, these multimodal brain
imaging findings suggest that prenatal selective serotonin
reuptake inhibitor exposure has a significant association with fetal
brain development.
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DisordersandSchizophrenia (SADS), a semistructureddiagnos-
tic interview.18Owing to time limitations, 20of the98mothers
withusable infantMRIdatadidnotcomplete theSADS (SSRI,2;
PMD, 5; andHC, 13). Postnatal depressionwas assessed via the
CES-D,whichwascompletedbymothersagainatthetimeoftheir
infant’sMRI session.
Infant 5-HT Transporter–Linked Polymorphic Region
Genotype
Todetermine infant 5-HT transporter–linkedpolymorphic re-
gion (5-HTTLPR) genotype, saliva sampleswere collected and
genotyped (eMethods in theSupplement).Genotypedatawere
missing for 9 infants, who were excluded from 5-HTTLPR
analyses.
MRI Acquisition and Analysis
Structural and diffusion MRI was acquired on a whole-body
scanner (MR 750 3T; GE Healthcare) with an 8-channel head
coil; eMethods in the Supplement provides details.
A T2-weighted structural MRI (single run) and diffusion-
weighted images (2 runs) were obtained from 98 infants; 80
infants had usable T2-weighted scans and 91 had at least 1 us-
able diffusion-weighted imaging run (eTable 2 in the Supple-
ment). TheT2-weighted imagesunderwent voxel-basedmor-
phometry. After preprocessing, diffusion-weighted imaging
underwent probabilistic tractography and a recently devel-
oped filtering algorithmto curtail false-positive streamline es-
timatesand improvethequantitative interpretabilityof stream-
line-based connectivity measures (eMethods in the
Supplement provide details).
Statistical Analysis
For both GM morphometry and WM connectivity, linear re-
gressionwithpermutation testing (nonparametric)wasused.
To examine the effects of SSRI exposure beyond the effects of
PMD exposure, primary contrast maps compared the SSRI
group vs both PMDandHC infants. Three follow-up contrasts
were then conducted, comparing (1) SSRI-exposed vs HC in-
fants, (2) SSRI- vs PMD-exposed infants, and (3) PMD-
exposed vs HC infants. The following covariates were in-
cluded in the initial regressionmodel: infant sex, age at scan,
birth weight, and mother's postnatal depression score, in-
dexed via the CES-D. Significance of effects was determined
using nonparametric permutation tests, which do not as-
sumeGaussiandistributions.Tocontrol for type Ierror invoxel-
based morphometry, we used conditional Monte Carlo per-
mutation testing (randomize program in Functional MRI of
Brain Software Library [FSL] v5.0; 10000permutations)with
the cluster-extent thresholdoption (a cluster-forming thresh-
old of z = 3.1; whole-brain correction).
For WM connectivity data, we used both connection-
level andwhole-brainconnectome-level analysis.Connection-
level analysis used the same linear regression model as de-
scribed above with exhaustive permutation testing in the
ImPerm r package (https://cran.r-project.org/web/packages
/lmPerm/index.html).Whole-brainconnectome-level analysis
was done with the Network-Based Statistics Toolbox (NBS,
version 1.2).20 We used 2 methods to control for type I error:
false discovery rate and network-based statistics. These
methodsare complementarybecause falsediscovery rate tests
thenullhypothesis at the individual connection level,whereas
network-basedstatistics testsat thenetwork levelusing family-
wiseerror.Falsediscovery rate ismoresensitive to focaleffects,





Magnetic resonance imaging scans were collected from 103
term infants, 98 of whom had usable MRI data. Five infants
were excluded owing to apparent imaging artifacts resulting
from excessive head motion. Specific subsamples for each
imagingmodalitywere structuralMRI in 80 infants (SSRI, 14;
PMD, 19; andHC,47) anddiffusionMRI in92 infants (SSRI, 14;
PMD, 20; and HC, 58). Groups did not differ significantly on
infantgestational ageatbirth, sex, andbirthweight (allP > .05;
analysis of variance) (Table 1). No significant group differ-
ences were detected in the number of nondepressive psychi-
atricdisordersdocumentedwith theSADSmeasure.Groupdif-
ferences were detected for infant age at MRI scan, maternal
age,maternal race/ethnicity, and total family income (Table 1).
SSRI Exposure and GMVolume
Comparedwith infantsnot exposed toSSRIs (ie, PMDandHC),
SSRI-exposed infants showeda significantGMvolumeexpan-
sion in the right amygdala and insulawithmediumto large ef-
fect sizes (SSRIvsPMDandHC: rightamygdala,Cohend = 0.65;
95%CI, 0.06-1.23; right insula, Cohend = 0.86; 95%CI, 0.26-
1.14) as well as in the right superior frontal gyrus and the left
occipital gyrus at a whole-brain corrected P value <.05 (ran-
domization permutation; adjusted for standard covariates)
(Figure 1 andTable2). Anunadjustedmodel also showeda sig-
nificant increase in volume in the right amygdala and right in-
sula at whole-brain corrected P < .05.
Comparedwith PMD infants alone, SSRI-exposed infants
showed a significant increase in volume in the right amyg-
dala, right insula, right superior frontal gyrus, and right pre-
cuneus atwhole-brain correctedP < .05 (Figure 1 andTable 2).
Furthermore, compared with HC infants alone, SSRI-
exposed infants showeda significant increase involume in the
right amygdala, right insula, and right caudate. No regions
showedadecrease inGM intensity in the SSRI-exposed group
atwhole-brain correctedP < .05.Therewerenosignificantdif-
ferences in GM volumes between the PMD and HC groups.
SSRI Exposure andWMConnectivity
Linear regression of the structural connectome (connectivity
was defined as streamline counts) revealed a significant in-
crease in connectivity in the SSRI group relative to all infants
not exposed to SSRIs (SSRI vs PMD andHC) in the following 4
connections: right amygdala-right insula, left anterior cingu-
late cortex-left thalamus, right precentral gyrus-right cu-
neus, and left insula-right precuneus at P < .05 (permutation
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testing; null hypothesis testing at the individual connection
level using false discovery rate). An unadjusted model simi-
larly showedasignificant increase inconnectivitybetween the
right amygdalaand right insulaandbetween the left insulaand
right precuneus atP < .05.However, at thenetwork level (net-
work-based statistics), the structural connectome showedno
significant group differences, suggesting similar topology of
the structural connectomes across the 3 groups (Figure 2A).
Fractional anisotropy and mean diffusivity of the structural
connectomes showednosignificant effectsof groupatP < .05.
Given the significant increase in GM volumes in the
right amygdala and right insula in the SSRI group (Figure 2B
and C), we performed a separate analysis focusing on WM
connectivity between the 2 regions to better estimate the
effect size. With a large effect size, linear regression showed
an increase in structural connectivity in the SSRI-exposed
group relative to all non–SSRI-exposed infants (SSRI vs PMD
and HC: t = 4.82; P < .001; Cohen d = 0.99; 95% CI, 0.40-
1.57; adjusted for the aforementioned covariates). Also with
large effect sizes, the SSRI group showed an increase com-
pared separately with either HC (SSRI vs HC: t = 4.68;
P < .001; Cohen d = 0.97; 95% CI, 0.36-1.57) or PMD (SSRI vs
PMD: t = 3.82; P < .001; Cohen d = 1.16; 95% CI, 0.41-1.89).
We confirmed these results in an additional tractography
analysis with a larger total streamline count (ie, 100 million
for initial tractography and 5 million for the streamline fil-
tering analysis).
Potential Confounders
Effects of SSRIs on GM volume expansion and increased
WM connectivity remained significant after adjusting for
maternal age, maternal race/ethnicity, total household
income, maternal education, maternal comorbid psychiatric
disorders, and infant 5-HTTLPR genotype (eTable 3 and
eResults in the Supplement).
Prediction of Brain Changes AssociatedWith Prenatal SSRI
Exposure
We assessed the capability of the selected GM and WMmea-
sures (amygdala volume, insula volume, and amygdala-
insula tract estimate) to predict prenatal SSRI exposure
(Figure 3). A logistic regression model with both GM and












4.29 (1.81) 3.03 (1.65) 3.30 (1.27) F2,95 = 3.82 .02
Gestational age
at birth, mean (SD),
wk
38.71 (1.00) 39.32 (1.04) 39.43 (1.06) F2,95 = 3.08 .05
Sex χ22 = 0.84
Male 8 8 30
.65
Female 8 13 31
Infant birth weight,
mean (SD), g
3754.19 (1320.23) 4000.57 (755.81) 3888.78 (746.28) F2,95 = 0.37 .69
Maternal age,
mean (SD), y
33.12 (4.20) 27.55 (6.57) 31.04 (5.75) F2,95 = 4.72 .01
Maternal
race/ethnicity
χ 26 = 20.91
Hispanic/Latina 0 7 19




Other 3 3 9
Total family income,
$
χ 26 = 37.98
0-25 000 1 13 13
<.001
26 000-50 000 1 4 16
51 000-100 000 2 2 20
>100 001 12 2 11
Infant SERT genotype χ 26 = 2.66
Long/long 4 8 21
.61Short/long 4 7 28
Short/short 4 2 9




4d 3e 5f χ 22 = 2.91 .23
Maternal CES-D,
prenatal, mean (SD)
12.63 (12.12) 24.33 (7.22) 7.22 (3.99) F2,95 = 51.80 <.001
Maternal CES-D,
postnatal, mean (SD)
10.84 (11.44) 15.8 (9.39) 6.98 (4.86) F2,95 = 11.54 <.001
Abbreviations: CES-D, Center For
Epidemiologic Studies Depression
scale; HC, healthy control; MDD,
major depressive disorder; PMD,
prenatal maternal depression; SADS,
Schedule for Affective Disorders and
Schizophrenia; SERT, serotonin
transporter; SSRI, selective serotonin
reuptake inhibitor.
a Exposure to low-level (n = 4),
midlevel (n = 7), and high-level
(n = 5) SSRI dosage (eMethods in
the Supplement) in the first (n = 1),
second (n = 2), and third (n = 13)
trimesters.
bWith diagnosis based on SADS
score18: major depressive disorder
(n = 3) and depressive disorder not
otherwise specified (n = 3).
c With diagnosis based on SADS
score: major depressive disorder
(n = 4) and depressive disorder not
otherwise specified (n = 12).
dWith diagnosis based on SADS
score: bulimia (n = 1), panic disorder
(n = 2), generalized anxiety disorder
(n = 1), and obsessive-compulsive
disorder (n = 1).
e With diagnosis based on SADS
score: posttraumatic stress disorder
(n = 1), panic disorder (n = 2),
agoraphobia (n = 1),
obsessive-compulsive disorder
(n = 1), and simple phobia (n = 1).
f With diagnosis based on SADS
score: posttraumatic stress disorder
(n = 1) and simple phobia (n = 4).
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WM (GM and WM model) showed the greatest area under
the curve (AUC) of 0.83 (95% CI, 0.63-0.93; leave-1-out
cross-validation), significantly greater than models with
either WM (P = .008, Wilcoxon rank sum test; AUC, 0.74;
95% CI, 0.51-0.87) or GM (P = .003; AUC, 0.67; 95% CI, 0.45-
0.84) alone. The GM and WM model with randomly per-
muted group labels showed an AUC of 0.41 (1000
iterations).
Discussion
Toourknowledge, this is the first study to report increasedvol-
umes of the amygdala and insular cortex, aswell as increased
WM connection strength between these 2 regions, in prena-
tally SSRI-exposed infants.Our findings suggest apotential as-
sociation between prenatal SSRI exposure, likely via aberrant














































Increase in GM volume in SSRI-exposed infants within amygdala and insulaB
Right amygdala Right insula
Increase in GM volume in SSRI-exposed infants across the brainA
SSRI > PMD
x = 28 x = 17 x = 3
y = 8
x = −19
z = −6 z = −10
y = −1 y = −4






































A, Significant group volume differences in infant brains (mean, 4 weeks).
Regression analyses were conducted on gray matter (GM) volumemaps,
estimated from T2-weightedmagnetic resonance imaging and through
voxel-basedmorphometry, using a whole-brain corrected P < .05
(randomization permutation; cluster-extent based correction). The colored
areas show an increase in volume in SSRI-exposed infants relative to prenatal
maternal depression (PMD) without SSRI exposure (green), healthy controls
(HC) (blue), and both groups combined (orange) (SSRI, n = 14; PMD, n = 19; HC,
n = 47). Compared with the PMD, HC, and both groups combined, the SSRI
group showed significant expansion in volume in the right amygdala and insula
compared with the PMD group and combined groups only in the superior
frontal gyrus, and compared with combined groups only, the occipital gyrus. B,
Distribution (colored area), quartiles (thick bar), 95% CIs (thin line), and
medians (white dots). Open triangles represent individual infant values. The
significance of group differences was based on voxelwise analysis (whole-brain
corrected using randomization permutation) from the 2 separate clusters in the
right amygdala and the anterior insula. au indicates arbitrary unit; c, cortex; g,
gyrus.
a P = .03 compared with both the PMD group, P = .02 compared with the HC
group, and P = .01 compared with the PMD and HC groups combined, all
significant results.
bP = .34 compared with the HC group.
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serotonin signaling, and the development of the amygdala-
insula circuit in the fetal brain.
Expression patterns of the 5-HT transporter in the devel-
oping brainmay underlie the association of prenatal SSRI ex-
posurewith alteredbrainmorphology. Exclusively during the
prenatal period, 5-HT transporter is expressed in serotoner-
gic neurons (eg, dorsal raphe) as well as nonserotonergic re-
gions across the brain, such as corticolimbic and sensorimo-
tor systems, as commonly seen in rodents,21 nonhuman
primates,22andhumans.5Expression innonserotoninergiccells
is then repressed after birth.23 It is thus possible that the tran-
sient prenatal expression of the 5-HT transporter in nonsero-
tonergic systems may render the fetal vs postnatal brain dif-
ferentially sensitive to SSRI exposure.
Our finding of increasedGMvolume in the amygdala, an-
terior insula, and superior frontal gyrus in prenatally SSRI-
exposed infants is in line with findings from animal studies.
In 5-HT transporter knockout mice, studies have shown
Figure 2.WhiteMatter (WM) Structural Connections in InfantsWith Prenatal Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs)
Estimated WM connections
in each group
























A,White matter structural connectomes (90 regions) estimated using diffusion
tractography; across both hemispheres, similar connectome organization was
evident in each study group: healthy control (HC) infants, SSRI-exposed infants,
and prenatal maternal depression (PMD)-exposed infants without SSRI
exposure (permutation tests against 1000 randomized connections; P < .05;
SSRI, n = 14; PMD, n = 20; HC, n = 58). B, Upper row shows amap of significant
group differences inWM connectivity. Regression analyses were conducted on
the connectivity matrix using a whole-brain-corrected P < .05 (randomization
permutation; false discovery rate control). Lower row shows a representative
WM pathway connecting the right amygdala (red) and the right insula (yellow)
color-coded by direction. C, Distributions (colored area), quartiles (thick bar),
95% CIs (thin line), andmedians (white dots). Open triangles represent infants.
The significance of the group differences was based on a regressionmodel
performed on the right amygdala-right amygdala connectivity (exhaustive
permutations).
a P < .001 compared with the PMD group, P < .001 compared with the HC
group, and P = .001 compared with the PMD and HC groups combined.
bP = .80 compared with the HC group.
Table 2. Group Comparison of GrayMatter Volumes (Voxel-BasedMorphometry)
Brain Region
Coordinates
x, y, z, mm
Whole-Brain Corrected
P Valuea Cluster Size, mm3
Contrast: SSRI>PMD + HC
Right amygdala 17, −1,−11 = .01 397
Right insula/orbitofrontal cortex 28, 8, −5 .01 50
Right superior frontal gyrus 3, 7, 36 .03 129
Left occipital gyrus −20,−63, 9 .04 116
Contrast: SSRI>PMD
Right amygdala 16, −2,−12 .03 65
Right insula/orbitofrontal cortex 29, 9, −6 .03 70
Right superior frontal gyrus 3, 10, 35 .03 35
0, 14, 29 .03 19
Right precuneus 29, 9, −6 .03 70
Contrast: SSRI>HC
Right amygdala/insula 15, −2, 08 .02 211
Right caudate 7, 0, −2 .02 26
Contrast: SSRI>PMD + HC
Right amygdala 17, −1,−11 .01 397
Right insula/orbitofrontal cortex 28, 8, −5 .01 50
Right superior frontal gyrus 3, 7, 36 .03 129
Left occipital gyrus −20,−63, 9 .04 116
Abbreviations: HC, healthy control;
PMD, prenatal maternal depression;
SSRI, selective serotonin reuptake
inhibitor.
a Significance was determined using
randomization permutation.
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increaseddendritic spinedensity in the amygdala24,25 and in-
creased dendritic branching of pyramidal neurons of the in-
fralimbic cortex.25 Studies also point to effects of pharmaco-
logic blockade of the 5-HT transporter in rodents during the
immediate postnatal period (ie, comparable to third-
trimester gestation in humans) with subsequent increased
anxiety anddepression-likebehaviors.3,26However, thesebe-
havioral sequelae emerged only after the rodents entered
puberty,3 much like what has been observed in a birth cohort
study of children with gestational SSRI exposure.14
Coordinationoftheamygdalaandinsuladuringthreataware-
ness isessential toadaptive fear regulation.27,28Ameta-analysis
of functionalbrain imagingstudies indicates that fearcondition-
ing is associatedwith task-relatedactivations inboth theamyg-
dalaand insula inhealthy individuals,29andanalogous findings
are reported in individuals with high trait anxiety.30 Similarly,
thecoordinationof theamygdalaandinsula isessentialnotonly
for fear conditioning, but also for anticipatoryanxiety, particu-
larly under conditions of uncertainty.31,32
Abnormalities in the amygdala-insula circuitrymay be as-
sociatedwithanxietyanddepression.33 Increasedamygdalavol-
umes are seen in both children and adults with anxiety
disorders,34-36heightenedamygdalaandinsulatask-relatedfunc-
tionalMRI activations are evident in adultswith anxietydisor-
dersduringthepresentationoffearfulstimuli,29andresting-state
functionalMRI studies showincreased functional connectivity
betweentheamygdalaandinsulaingeneralizedanxietyandpost-
traumatic stress disorder.37,38 Similar functional connectivity
findingsare reported inchildrenandadolescentsacrossa range
of anxiety disorders and symptoms.34,39,40 This abnormal
amygdala-insulacircuitrymaybeassociatedwith increasedvul-
nerability to anxiety and/or other mood disorders. Amygdala-
insula hyperactivity to threats is reported in peoplewho are at
risk but not yetmeeting criteria for anxiety disorders, suggest-
ingthathyperactivity inthiscircuitmayindexincreasedsuscep-
tibility to anxiety disorders.30 Taken together, the structurally
primedcircuit in the infantbrainscould leadtomaladaptive fear
processingintheir later life,suchasgeneralizationofconditioned
fear or negative attention bias.
Prior infant neuroimaging studies report seemingly
mixed findings: increased fractional anisotropy of the supe-
rior WM pathway16 and decreased fractional anisotropy and
increased mean diffusivity 17 of the WM pathways. How-
ever, the first study had no direct comparison of exposure to
both SSRI and PMD vs exposure with PMD alone and, in the
second study, the association between prematurity and
neurodevelopment might confound the results.
The effects of SSRIs were present only in the right hemi-
sphere. One study hints at asymmetric distributions of 5-HT
receptors. In healthy adults, 5-HT1A receptor binding esti-
mated by positron emission tomography is higher in the
right frontal gyri relative to their left hemispheric counter-
parts (and higher in the left auditory cortex).41 It remains to
be determined whether the asymmetric expression pattern
of 5-HT transporter in adults is also present during the fetal
period.
Limitations
Our findings should be interpreted in the context of a few
limitations. First, because participants were not randomly
assigned to the PMD or SSRI group, there could be unmea-
sured sample differences. It is possible that women who
received an SSRI during pregnancy were more severely
depressed than were those with PMD. Because our assess-
ments of depression occurred when women were already
receiving the SSRI, this hypothesis requires further investi-
gation. Future human studies could include randomization
and placebo control (eg, clinicaltrials.gov Identifier:
NCT02185547). Second, the groups in our study differed in
sociodemographics (maternal education, income, race/
ethnicity, and birth weight). Although we statistically
adjusted for these potential confounding variables, future
research will be needed to conclusively disentangle SSRI
and PMD exposure from these sociodemographic variables.
Third, the behavioral and psychological correlates of our
volumetric and connectivity findings need to be determined
and longitudinal studies will need to examine whether
developmental trajectories are affected. Last, the accuracy
(eg, sensitivity, but perhaps not reliability42) of the fiber ori-
entation estimates in diffusion probabilistic tractography
might be partially limited by a relatively small number of
gradient directions (n = 11). However, our selection of scan-
ning parameters was based on multiple factors, not solely
on the number of gradient directions, such as spatial resolu-
tion (submillimeter in-plane resolution for the small neona-
tal brains), scan duration, and signal-to-noise ratio that
decreases as the number of gradient directions increases.
Figure 3. Selected GrayMatter (GM) andWhiteMatter (WM)Measures
AssociatedWith Brain Changes After Prenatal Exposure to Selective


























Receiver operating characteristics analysis curve showing cross-validated
diagnostic accuracy of a linear regressionmodel predicting SSRI exposure
(leave-1-out cross validation). We tested 3 logistic regressionmodels with
different sets of the selected brain measures as predictors: GM+WM (orange),
WM (gray), and GM (blue) models (predictors: for GM, right amygdala volume
and right insula volume; for WM, amygdala-insula connectivity). Shaded areas
are confidence bounds (estimated in 5000 bootstrap samples).
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Conclusions
Use of SSRIs during pregnancy has increased in recent
decades,43 yet their association with fetal neurodevelop-
ment continues to be a topic of considerable debate. Because
untreatedPMDposes risks toboth the infantandmother,2,44-46
the decision to initiate, continue, or suspend SSRI treatment
remains a clinical dilemma. Preclinical studies of rodents in-
dicate that dose, timing, andmechanismof action (5-HT aug-
menting or not) all contribute to outcomes in later life.3,9,10,47
Further study is required tobetter elucidate the effects of ges-
tational SSRI exposure on fetal brain development and later
life susceptibility to depressive, cognitive, and motor abnor-
malities. Such information may eventually allow more in-
formed clinical decisions about how to best treat psychiatric
disordersduringpregnancy for thebenefit of bothmother and
fetus.
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